[HTML][HTML] Primary hyperfibrinolysis in liver disease: a critical review
N Bennani-Baiti, HA Daw - Clin Adv Hematol Oncol, 2011 - hematologyandoncology.net
N Bennani-Baiti, HA Daw
Clin Adv Hematol Oncol, 2011•hematologyandoncology.netDiscussion In patients with cirrhosis, the fibrinolytic pathway is activated by an increased
endothelial release of tissue plasminogen activator (t-PA), decreased hepatic clearance of t-
PA, decreased thrombin activatable fibrinolysis inhibitor, and decreased synthesis of alpha-
2 antiplasmin and plasminogen activator inhibitor. 1, 3 Hyperfibrinolysis in cirrhotic patients
usually causes mucocutaneous bleeding, but it can also cause gastrointestinal bleeding. 4
endothelial release of tissue plasminogen activator (t-PA), decreased hepatic clearance of t-
PA, decreased thrombin activatable fibrinolysis inhibitor, and decreased synthesis of alpha-
2 antiplasmin and plasminogen activator inhibitor. 1, 3 Hyperfibrinolysis in cirrhotic patients
usually causes mucocutaneous bleeding, but it can also cause gastrointestinal bleeding. 4
Discussion
In patients with cirrhosis, the fibrinolytic pathway is activated by an increased endothelial release of tissue plasminogen activator (t-PA), decreased hepatic clearance of t-PA, decreased thrombin activatable fibrinolysis inhibitor, and decreased synthesis of alpha-2 antiplasmin and plasminogen activator inhibitor. 1, 3 Hyperfibrinolysis in cirrhotic patients usually causes mucocutaneous bleeding, but it can also cause gastrointestinal bleeding. 4
hematologyandoncology.net
